Marken Announces New Operations Center in Zurich
News Aug 19, 2016
Marken has announced the opening of their latest GDP-compliant operations center in Zurich, Switzerland, responding to increased demand from local pharmaceutical companies with growing clinical development programs. The new location is within close vicinity to the Zürich Airport (Kloten) freight terminal and is strategically located near major Swiss highways.
The facility, which operates 24/7/365, includes office and warehouse space with refrigerators and freezers available for temperature controlled packaging, full security and is connected to Marken’s global ‘Maestro’ operating system. The operation will be fully staffed, capable of collecting and shipping clinical drug product from the Zurich gateway to anywhere in the world. The facility also conforms to the Swiss Minergie (green) standard, a registered quality label for new and refurbished low-energy-consumption buildings.
Wes Wheeler, Chief Executive Officer for Marken, commented, “Marken has built a global logistics network specifically designed to meet the needs of the global pharmaceutical industry. Our newest site in Zurich replaces our smaller office with expanded capabilities so that we can be ready for the increased clinical logistics demands from our clients. We have also set the standard for GDP compliance – especially in Europe – and will certify the operations according to our own ‘Gold Book’ standard.”
Wheeler concluded: “We are the only 100%-dedicated, patient centric supply chain organization in the life sciences industry. We will continue to expand our global footprint to meet the increasingly demanding requirements of our clients.”
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Cocaine Use Alters Gene Expression in Brain Reward CircuitsNews
A study in Biological Psychiatry investigates transcriptome-wide alterations in response to cocaine self-administration in mice.
Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development PartnershipNews
MD Anderson will progress the drug candidate through Phase I clinical development with Ipsen being responsible for further global development and commercialization.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018